Ovarian Hyperstimulation Syndrome: Clinical Trials

7 trials for Ovarian Hyperstimulation Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 suspended, 1 unknown. 7 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Suspended 1, Unknown 1
Phase 12Completed 2

Follow Ovarian Hyperstimulation Syndrome: new trials by email Literature Review of Ovarian Hyperstimulation Syndrome trials Research Report on Ovarian Hyperstimulation Syndrome

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
Fludrocortisone 0.1 Milligrams (mg), Bromocriptine - Ovarian Hyperstimulation Syndrome
Phase 2CompletedGanin Fertility Center1072019-04-012020-04-17
Montelukast for Prevention & Treatment of OHSS
dydrgesterone 10 mg( tab)/12hs/14 days, montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days - Ovarian Hyperstimulation Syndrome
Phase 2SuspendedBenha University202018-12-052022-09-21
Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome
bromocriptine, dexamethasone - Ovarian Hyperstimulation Syndrome
Phase 2UnknownSun Yat-sen University2002016-08-012016-07-27
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
Methylprednisolone, Control - Ovarian Hyperstimulation Syndrome
Phase 1 / Phase 2CompletedRoyan Institute2182009-10-012011-07-15
Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program
Cabergoline, Control - Ovarian Hyperstimulation Syndrome
Phase 1 / Phase 2CompletedRoyan Institute102009-06-012015-05-06
Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
Quinagolide - Ovarian Hyperstimulation Syndrome
Phase 2CompletedInstituto Valenciano de Infertilidad, IVI VALENCIA302008-05-012009-09-17
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
Norprolac - Ovarian Hyperstimulation Syndrome
Phase 2CompletedFerring Pharmaceuticals1822006-06-012011-05-19

Broader conditions

Adnexal Diseases (7)  ·  Endocrine System Diseases (7)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Genital Diseases (7)  ·  Genital Diseases, Female (7)  ·  Gonadal Disorders (7)  ·  Ovarian Diseases (7)  ·  Urogenital Diseases (7)

Interventions

Bromocriptine (2)  ·  quinagolide (2)  ·  Cabergoline (1)  ·  Dexamethasone (1)  ·  Methylprednisolone (1)  ·  Tablets (1)  ·  montelukast (1)

Sponsors

Royan Institute (2)  ·  Benha University (1)  ·  Ferring Pharmaceuticals (1)  ·  Ganin Fertility Center (1)  ·  Instituto Valenciano de Infertilidad, IVI VALENCIA (1)  ·  Sun Yat-sen University (1)

Countries

Egypt (2)  ·  Iran (2)  ·  Spain (2)  ·  China (1)

Top investigators

Ashraf Moini, MD (2)  ·  Marzieh Shiva, MD (2)  ·  Eniseh Tehraninejad, MD (1)  ·  Haitao Zeng (1)  ·  Hosam Zaki, MSc, FRCOG (1)  ·  Hossam Elattar, MBBCH (1)  ·  Muhammad S Zeafan, MBBCH (1)

Results publications

PMID 20139430, PMID 22231013, PMID 33851429